Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 983Neoplasms 777Carcinoma, Non-Small-Cell Lung 750Prostatic Neoplasms 587Colorectal Neoplasms 508Lung Neoplasms 450Neoplasm Metastasis 413Multiple Myeloma 377Leukemia, Myeloid, Acute 359Ovarian Neoplasms 317Pancreatic Neoplasms 304Melanoma 277Squamous Cell Carcinoma of Head and Neck 261Recurrence 254Carcinoma, Hepatocellular 236Glioblastoma 229Brain Neoplasms 226Head and Neck Neoplasms 204Triple Negative Breast Neoplasms 201Carcinoma, Renal Cell 201Lymphoma 194Precursor Cell Lymphoblastic Leukemia-Lymphoma 193Stomach Neoplasms 189Endometrial Neoplasms 183Lymphoma, Non-Hodgkin 176Sarcoma 171Glioma 168Uterine Cervical Neoplasms 167Lymphoma, Large B-Cell, Diffuse 163Hematologic Neoplasms 163

Interventions

mirdametinib 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Primary Malignant Peripheral Nerve Sheath Tumors × 90 days × Clear all
NCT06693284 2026-05-29

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

University of Minnesota

Phase EARLY_PHASE1 Recruiting
8 enrolled

Primary Malignant Peripheral Nerve Sheath Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡